Niva Bupa Health Insurance has announced significant changes to its leadership team, including the appointment of two new Non-Executive Directors, Mr. Christopher Patrick Carroll and Ms. Siobhan Djihan Moynihan, effective May 15, 2026. Additionally, the company has elevated Mr. Ankur Kharbanda to Executive Director and Deputy CEO. Concurrently, the Board approved a grant of 12,251,268 Employee Stock Options (ESOPs) under the 2024 scheme at a price of ₹72.45 per option.
Leadership Appointments and Restructuring
The company has strengthened its Board of Directors with the appointment of two additional Non-Executive Directors, Mr. Christopher Patrick Carroll and Ms. Siobhan Djihan Moynihan. These appointments are set to take effect on May 15, 2026. Furthermore, the company has announced the elevation of Mr. Ankur Kharbanda, who previously served as Executive Director and Chief Business Officer, to the role of Executive Director and Deputy Chief Executive Officer, effective May 8, 2026.
Departure of Non-Executive Directors
The company also acknowledged the resignation of two Non-Executive Directors, Ms. Penelope Ruth Dudley and Mr. Carlos Antonio Jaureguizar Ruiz-Jarabo. Both resignations are effective from the close of business hours on May 8, 2026. These departures were attributed to the individuals having limited time to devote to company affairs due to their other professional commitments.
Employee Stock Option Plan Update
In addition to leadership updates, the company has approved the grant of 12,251,268 employee stock options to eligible staff members under the Niva Bupa Employee Stock Option Plan 2024. The exercise price for these options has been set at ₹72.45 per share, determined by the weighted average price of company shares during March 2026. These options come with a maximum exercise period of four years from the date of vesting.
Source: BSE
